All Clarivate websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.

More information on our cookie policy.

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
  • Special reports
    • Artificial intelligence
    • Coronavirus
    • IVDs on the rise
    • Top Biopharma Trends of 2021
    • Top Med-tech Trends of 2021
    • Premium reports
      • BioWorld Financings Reports
      • Disease Incidence & Prevalence Summaries

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Monday, May 16, 2022

Diagnostics

  • Diagnostics
    • Artificial intelligence
    • Biopsy
    • Electrocardiogram
    • Genomics
    • Imaging
    • Liquid biopsy
    • Monitoring
    • Point-of-care
Home » Topics » Medical devices and technologies » Diagnostics
  • May 12, 2022
    By Mari Serebrov

    US NIH COVID-19 technologies going global

    In an effort to increase global access to COVID-19 technologies, the World Health Organization’s COVID-19 Technology Access Pool and the Medicines Patent Pool finalized a licensing agreement May 12 with the U.S. NIH for research tools, early stage vaccines and diagnostics.
  • Covid 19 coronavirus us digital
    May 10, 2022
    By Mark McCarty

    Contamination at root of class I recall of Mesa Biotech’s Accula COVID test

    The in vitro diagnostics industry has turned in an impressive response to the COVID-19 pandemic, but a few problems are bound to surface. The U.S. FDA reported May 10 that the Accula test by San Diego-based Mesa Biotech Inc. has been recalled due to contamination of test materials at the manufacturing site, a problem that could lead to false negative findings with the test.
  • 01 21 oncohost
    May 10, 2022
    By Annette Boyle

    Oncohost’s $35M series C predicts expansion of Prophet study

    The short-term future is a little clearer for Israeli precision oncology startup Oncohost Ltd. now that it has closed a $35 million series C fundraising round. The new infusion more than doubled the previous amount raised, bringing total investment to more than $50 million. The company plans to use the funds to expand its PROPHETIC trial of the company’s machine learning-based host response profiling platform, Prophet, to additional locations worldwide and new indications.
Read More

Blog Posts

  • Docgraham
    Nov. 6, 2014
    By Omar Ford

    Combination diagnostics lead discussion for Cleveland Clinic's Medical Innovation Summit

  • Aug. 2, 2013
    By Amanda Pedersen

    Screening saves lives, but criteria too narrow

  • July 26, 2013
    By Omar Ford

    Faster results from diagnostics could reduce anxiety

  • May 22, 2013
    By Amanda Pedersen

    Jamar Rogers: living his best life

  • May 16, 2013
    By Robert Kimball

    To sleep, perchance to analyze data?

Read More

Authors

  • Mark McCarty
  • Holland Johnson
  • Amanda Pedersen
  • Omar Ford
  • Robert Kimball
  • Tamra Sami
More Authors
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Archives
    • Today's news
    • Search BioWorld Science
    • About
  • More
    • About
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
Follow Us

Copyright ©2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing